News | July 06, 2024
Biogen completes acquisition of HI-Bio
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
This tie-up will have no impact on any other brands of the company
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
Berlinger brings a suite of proprietary and high-quality hardware and software solutions that broaden Sensitech's end-to-end cold chain monitoring product portfolio
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
Subscribe To Our Newsletter & Stay Updated
